DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Analyst Optimism | Discover why analysts set price targets ranging from $7.39 to $21.15, reflecting confidence in DBV's pipeline and market potential |
Financial Crossroads | Delve into DBV's financial position, including its $128 million cash reserves and potential $180 million warrant exercise, as it approaches critical milestones |
Market Opportunity | Explore the vast potential of the pediatric peanut allergy market, with projected peak sales exceeding $2 billion for Viaskin Peanut |
Peanut Allergy Pionee | DBV Technologies leads innovation in food allergy treatment with Viaskin Peanut, a non-invasive epicutaneous immunotherapy showing promise in clinical trials |
Metrics to compare | DBVT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDBVTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.9x | 13.5x | −0.6x | |
PEG Ratio | −28.23 | −0.14 | 0.00 | |
Price / Book | 28.1x | 2.8x | 2.6x | |
Price / LTM Sales | 270.3x | 3.9x | 3.4x | |
Upside (Analyst Target) | 90.7% | 37.8% | 42.0% | |
Fair Value Upside | Unlock | 11.5% | 5.0% | Unlock |